P-Glycoprotein Mediated Drug Interactions in Animals and Humans with Cancer

Journal of Veterinary Internal Medicine

Volumn 29, Issue 1, 2015, Pages 1-6

  Mealey, K L ^a   Fidel, J ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

ABCB1; Chemotherapy; Doxorubicin vincristine; Drug Interaction; Ketoconazole; MDR1; Oncology; Spinosad

Indexed keywords

ANIMALIA;

ANTINEOPLASTIC AGENT; MULTIDRUG RESISTANCE PROTEIN;

ANIMAL; DRUG INTERACTION; HUMAN; METABOLISM; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG INTERACTIONS; HUMANS; NEOPLASMS; P-GLYCOPROTEIN;

EID: 84921531852     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/jvim.12525     Document Type: Review

References (49)

1. Leape LL, Bates DW, Cullen DJ, et al. Systems analysis of adverse drug events. ADE Prevention Study Group. J Am Med Assoc 1995;274:35-43.
2. Raschetti R, Morgutti M, Menniti-Ippolito F, et al. Suspected adverse drug events requiring emergency department visits or hospital admissions. Eur J Clin Pharmacol 1999;54:959-963.
3. Lazarou J, Pomeranz B, Corey PN. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. J Am Med Assoc 1998;279:1200-1205.
4. Marchetti S, Mazzanti R, Beijnen JH, Schellens JHM. Concise review: Clinical relevance of drug-drug and herb-drug interactions mediated by the ABC Transporter ABCB1 (MDR1, P-glycoprotein). Oncologist 2007;12:927-941.
5. Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 2005;204:216-237.
6. Mealey KL, Greene S, Bagley R, et al. P-glycoprotein contributes to the blood-brain, but not blood-cerebrospinal fluid, barrier in a spontaneous canine p-glycoprotein knockout model. Drug Metab Dispos 2008;36:1073-1079.
7. Choo EF, Leake B, Wandel C, et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 2000;28:655-660.
8. Iyer L, Ramirez J, Shepard DR, et al. Biliary transport of irinotechan and metabolites in normal and P-glycoprotein deficient mice. Cancer Chemother Pharmacol 2002;49:336-341.
9. Coelho JC, Tucker R, Mattoon J, et al. Biliary excretion of technetium-99 m-sestamibi in wild-type dogs and in dogs with intrinsic (ABCB1-1Delta mutation) and extrinsic (ketoconazole treated) P-glycoprotein deficiency. J Vet Pharmacol Ther 2009;32:417-421.
10. Callaghan R, Luk F, Bebawy M. Inhibition of the multidrug resistance P-glycoprotein: Time for a change of strategy. Drug Metab Disp 2014;42:623-631.
11. Mealey KL. Therapeutic implications of the MDR-1 gene. J Vet Pharmacol Ther 2004;27:257-264.
12. Dean M, Annilo T. Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. Annu Rev Genomics Hum Genet 2005;6:123-142.
13. DeGorter MK, Xia CQ, Yang JJ, Kim RB. Drug transporters in drug efficacy and toxicity. Annu Rev Pharmacol Toxicol 2012;52:249-273.
14. Ginn PE. Immunohistochemical detection of P-glycoprotein in formalin-fixed and paraffin-embedded normal and neoplastic canine tissues. Vet Pathol 1996;33:533-541.
15. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: An overview. Adv Drug Deliv Rev 2003;55:3-29.
16. Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett 2006;234:4-33.
17. Mealey KL, Bentjen SA, Gay JM, Cantor GH. Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics 2001;11:727-733.
18. Mealey KL, Fidel J, Gay JM, et al. ABCB1-1Delta polymorphism can predict hematologic toxicity in dogs treated with vincristine. J Vet Intern Med 2008;22:996-1000.
19. Schinkel AH. Pharmacological insights from P-glycoprotein knockout mice. Int J Clin Pharmacol Ther 1998;36:9-13.
20. Mealey KL, Meurs KM. Breed distribution of the ABCB1-1Delta (multidrug sensitivity) polymorphism among dogs undergoing ABCB1 genotyping. J Am Vet Med Assoc 2008;233:921-924.
21. Gramer I, Leidolf R, Doring B, et al. Breed distribution of the nt230(del4) MDR1 mutation in dogs. Vet J 2011;189:67-71.
22. Kawabata A, Momoi Y, Inoue-Murayama M, Iwasaki T. Canine mdr1 gene mutation in Japan. J Vet Med Sci 2005;67:1103-1107.
23. Mealey KL, Munyard KA, Bentjen SA. Frequency of the mutant MDR1 allele associated with multidrug sensitivity in a sample of herding breed dogs living in Australia. Vet Parasitol 2005;131:193-196.
24. Tappin SW, Goodfellow MR, Peters IR, et al. Frequency of the mutant MDR1 allele in dogs in the UK. Vet Rec 2012; 171: 72.
25. Neff MW, Robertson KR, Wong AK, et al. Breed distribution and history of canine mdr1-1Delta, a pharmacogenetic mutation that marks the emergence of breeds from the collie lineage. Proc Natl Acad Sci U S A 2004;101:11725-31170.
26. Nelson OL, Carsten E, Bentjen SA, Mealey KL. Ivermectin toxicity in an Australian Shepherd dog with the MDR1 mutation associated with ivermectin sensitivity in Collies. J Vet Intern Med 2003;17:354-356.
27. Sartor LL, Bentjen SA, Trepanier L, Mealey KL. Loperamide toxicity in a collie with the MDR1 mutation associated with ivermectin sensitivity. J Vet Intern Med 2004;18:117-118.
28. Paul AJ, Tranquilli WJ, Seward RL, et al. Clinical observations in collies given ivermectin orally. Am J Vet Res 1987;48:684-685.
29. Tranquilli WJ, Paul AJ, Seward RL. Ivermectin plasma concentrations in collies sensitive to ivermectin-induced toxicosis. Am J Vet Res 1989;50:769-770.
30. Kiso S, Cai SH, Kitaichi K, et al. Inhibitory effect of erythromycin on P-glycoprotein-mediated biliary excretion of doxorubicin in rats. Anticancer Res 2000;20:2827-2834.
31. Bansal T, Mishra G, Jaggi M, et al. Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. Eur J Pharm Sci 2009;36:580-590.
32. Castle MC, Margileth DA, Oliverio VT. Distribution and excretion of (3H)vincristine in the rat and the dog. Cancer Res 1976;36:3684-3689.
33. Reddy GK, Brown B, Nanda A. Fatal consequences of a simple mistake: How can a patient be saved from inadvertent intrathecal vincristine? Clin Neurol Neurosurg 2011;113:68-71.
34. Krugman L, Bryan JN, Mealey KL, Chen A. vincristine-induced central neurotoxicity in a collie homozygous for the ABCB1Δ mutation. J Sm An Pract 2012;53:185-187.
35. Dantzig AH, deAlwis DP, Burgess M. Considerations in the design and develoment of transport inhibitors as adjuncts to drug therapy. Adv Drug Deliv Rev 2003;55:133-150.
36. Bates S, Kang M, Meadows B, et al. A phase I study of infusional vinblastine in combination with the p-glycoprotein antagonist PSC 833 (valspodar). Cancer 2001;92:1577-1590.
37. Chico I, Kang MH, Bergan R, et al. Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833. J Clin Oncol 2001;19:832-842.
38. Varma MVS, Ashokraj Y, Dey CS, Panchagnula R. P-glycoprotein inhibitors and their screening: A perspective from bioavailability enhancement. Pharm Res 2003;48:347-359.
39. Dunn ST, Hedges L, Sampson KE, et al. Pharmacokinetic interaction of the antiparasitic agents ivermectin and spinosad in dogs. Drug Metab Dispos 2011; 39: 789-795.
40. Zhou XJ, Rahmani R. Preclinical and clinical pharmacology of vinca alkaloids. Drugs 1992;44S:1-16.
41. Hafkemeyer P, Dey S, Ambudkar SV, et al. Contribution to substrate specificity and transport of nonconserved residues in transmembrane domain 12 of human P-glycoprotein. Biochemistry 1998;37:16400-16409.
42. Bradley G, Ling V. P-glycoprotein, multidrug resistance and tumor progression. Cancer Metastasis Rev 1994;13:223-233.
43. Eadie LN, Hughes TP, White DL. Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib and dasatinib. Clin Pharmacol Ther 2014;95:294-306.
44. Fromm MF. The influence of MDR1 polymorphisms on P-glycorptoein expression and function in humans. Adv Drug Deliv Rev 2002;54:1295-1310.
45. Sakaeda T, Nakamura T, Okumura K. MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol Pharm Bull 2002;25:1391-1400.
46. Page RL, Hughes CS, Huyan S, et al. Modulation of P-glycoprotein-mediated doxorubicin resistance in canine cell lines. Anticancer Res 2000;20:3533-3538.
47. Ford JM, Hait WN. Pharmacological circumvention of multidrug resistance. Cytotechnology 1993;12:171-212.
48. Binkhathlan Z, Lavasanifar A. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: Current status and future perspectives. Curr Cancer Drug Targets 2013;13:326-346.
49. Ford JM. Modulators of multidrug resistance. Preclinical studies. Hematol Oncol Clin North Am 1995;9:337-361.